Biohaven Ltd. (BHVN) Stock

Biohaven Ltd. (BHVN) is a Healthcare stock trading at $13.55 (as of 2026-06-18), with a market capitalization of $1.53B and a trailing P/E of -2.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunoscience-related diseases. Its work centers on advancing treatment options for these conditions.

Valuation — source: SEC EDGAR (first-party)
Price$13.55
Market Cap$1.53B
P/E Ratio-2.0
EV / EBITDA-2.2
Price / Book13.11
DCF Value (model)$-67.51
DCF Upside vs Price-598.2%
Profitability & Growth — source: SEC EDGAR
Return on Equity-500.1%
Current Ratio7.41
Valuation vs Sector & Industry
Stock P/E-2.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-109.7%
vs Industry-111.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANUS HENDERSON GROUP PLC ($148.21M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOVladimir Coric
Employees256
CountryUS
IPO Date2022-09-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • uniQure N.V. (QURE)
  • Innoviva, Inc. (INVA)
  • Atai Beckley N.V (ATAI)
  • Precigen, Inc. (PGEN)
  • Oruka Therapeutics, Inc. (ORKA)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)
BHVN earnings history · BHVN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.